I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Group (including its affiliates) and Hony Capital (collectively, the "Key Shareholders") as well as its senior...
China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results
HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 2021. Full Year Highlights Revenue was $9.6 million in fiscal year 2021, compared to $10.9...
HOYA Group Appoints Rainer Burkard as Global President of PENTAX Medical
TOKYO, March 31, 2022 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has announced the appointment of Rainer Burkard to the position of Global President of PENTAX Lifecare Division (PENTAX Medical) as of April 1st, 2022. Rainer Burkard, Global President, PENTAX Medical "HOYA Group is pleased to have Mr. Rainer Burkard lead the global division of...
Tai Chi Training Can Effectively Improve Parkinson’s Disease and Mild Cognitive Impairment
HONG KONG, March 31, 2022 /PRNewswire/ -- The latest research shows that Tai Chi training is conducive to the treatment of Parkinson's disease and the prevention of Alzheimer's disease. Professor Shengdi Chen from the Neurology Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine has just published papers in the international authoritative medical journals, Translational Neurodegeneration and...
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAg observed in the Chinese patients infected with chronic hepatitis B DURHAM, N.C. and BEIJING, March 31, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant...
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in Europe GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced submission of its request...
Growing Leaders: How VISTA Eye Specialists have gained from its Upskilling Program using Gamification.
PETALING JAYA, Malaysia, March 31, 2022 /PRNewswire/ -- Started amidst the 1st year of COVD in Malaysia in 2020, VISTA Eye Specialists (VISTA), one of the leading Eye Specialists in Malaysia since 1999, implemented an Upskilling program to help the staff take the focus away from the COVID pandemic and focus on creating a positive workplace environment, where staff can...
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, Ga., March 31, 2022 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients...
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs Hasten fast-tracks transformative medicines for patients in China SHANGHAI, March 31, 2022 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired a portfolio of five prescription pharmaceutical products sold in China from Takeda Pharmaceutical Company Limited....
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
SHANGHAI, March 31, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a pivotal clinical trial of its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy...
